Venetoclax Plus Dexamethasone Misses PFS End Point in t(11;14)+ R/R Multiple Myeloma

The combination of venetoclax and dexamethasone failed to significantly improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive, relapsed or refractory multiple myeloma who have previously received at least 2 therapies.

Related Keywords

San Diego ,California ,United States ,Netherlands ,Amsterdam ,Noord Holland ,Venclexta Venclyxto ,Mariana Cota Stirner ,International Myeloma Working Group ,European Hematology Association Congress ,With Pomdex ,Cota Stirner ,Dimopoulosm A ,Hematology Association Congress ,Venetoclax ,Dexamethasone ,Pomalidomide ,Phase 3 Canova Study ,Myeloma ,